[1]
|
D. R. Youlden, S. M. Cramb and P. D. Baade, “The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends,” Journal of Thoracic Oncology, Vol. 3, No. 8, 2008, pp. 819-831.
doi:10.1097/JTO.0b013e31818020eb
|
[2]
|
S. G. Spiro and G. A. Silvestri, “One Hundred Years of Lung Cancer,” American Journal of Respiratory Critical Care Medicine, Vol. 172, No. 5, 2005, pp. 523-529.
doi:10.1164/rccm.200504-531OE
|
[3]
|
R. Califano, A. Z. Abidin, R. Peck, C. Faivre-Finn and P. Lorigan, “Management of Small Cell Lung Cancer: Recent Developments for Optimal Care,” Drugs, Vol. 72, No. 4, 2012, pp. 471-490.
doi:10.2165/11597640-000000000-00000
|
[4]
|
R. Govindan, N. Page, D. Morgensztern, et al., “Changing Epidemiology of Small-Cell Lung Cancer in the United States over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database,” Journal of Clinical Oncology, Vol. 24, 2006, pp. 4539-4544. doi:10.1200/JCO.2005.04.4859
|
[5]
|
W. N. William and B. S. Glisson, “Novel Strategies for the Treatment of Small-Cell Lung Carcinoma, “Nature Reviews Clinical Oncology, Vol. 8, No. 10, 2011, pp. 611-619. doi:10.1038/nrclinonc.2011.90
|
[6]
|
Y. Agra, M. Pelayo, M. Sacristan, et al., “Chemotherapy versus Best Supportive Care for Extensive Small Cell Lung Cancer,” Cochrane Database Systematic Review, Vol. 4, 2003, Article ID: CD001990.
|
[7]
|
M. Takada, M. Fukuoka, M. Kawahara, et al., “Phase III Study of Concurrent versus Sequential Thoracic Radiotherapy in Combination with Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 20, 2002, pp. 3054-3060.
doi:10.1200/JCO.2002.12.071
|
[8]
|
B. Fischer and A. Arcaro, “Current Status of Clinical Trials for Small Cell Lung Cancer,” Review of Recent Clinical Trials, Vol. 3, 2008, pp. 40-61.
doi:10.2174/157488708783330503
|
[9]
|
H. H. Berendsen, L. de Leij, E. G. de Vries, G. Mesander, N. H. Mulder, B. de Jong, C. H. Buys, P. E. Postmus, S. Poppema, H. J. Sluiter, et al., “Characterization of Three Small Cell Lung Cancer Cell Lines Established from One Patient during Longitudinal Follow-Up,” Cancer Research, Vol. 48, No. 23, 1988, pp. 6891-6899.
|
[10]
|
V. G. Tusher, R. Tibshirani and G. Chu, “Significance Analysis of Microarrays Applied to the Ionizing Radiation Response,” Proceedings of the National Academy of Science U S A., Vol. 98, No. 9, 2001, pp. 5116-5121.
doi:10.1073/pnas.091062498
|
[11]
|
D. Croft, G. O’Kelly, G. Wu, R. Haw, M. Gillespie, L. Matthews, M. Caudy, P. Garapati, G. Gopinath, B. Jassal, S. Jupe, I. Kalatskaya, S. Mahajan, B. May, N. Ndegwa, E. Schmidt, V. Shamovsky, C. Yung, E. Birney, H. Hermjakob, P. D’Eustachio and L. Stein, “Reactome: A Database of Reactions, Pathways and Biological Processes,” Nucleic Acids Research, Vol. 39, 2011, pp. D691-D697. doi:10.1093/nar/gkq1018
|
[12]
|
E. G. de Vries, C. Meijer, H. Timmer-Bosscha, H. H. Berendsen, L. de Leij, R. J. Scheper and N. H. Mulder, “Resistance Mechanisms in Three Human Small Cell Lung Cancer Cell Lines Established from One Patient during Clinical Follow-Up,” Cancer Research, Vol. 49, No. 15, 1989, pp. 4175-4178.
|
[13]
|
G. Rapp, J. Freudenstein, J. Klaudiny, J. Mucha, F. Wempe, M. Zimmer and K. H. Scheit, “Characterization of Three Abundant mRNAs from Human Ovarian Granulosa Cells,” DNA Cell Biology, Vol. 9, No. 7, 1990, pp. 479-485.doi:10.1089/dna.1990.9.479
|
[14]
|
M. H. Lawson, N. M. Cummings, D. M. Rassl, R. Russell, J. D. Brenton, R. C. Rintoul and G. Murphy, “Two Novel Determinants of Etoposide Resistance in Small Cell Lung Cancer,” Cancer Research, Vol. 71, No. 14, 2011, pp. 4877-4887. doi:10.1158/0008-5472.CAN-11-0080
|
[15]
|
A. Naderi, A. E. Teschendorff, J. Beigel, M. Cariati, I. O. Ellis, J. D. Brenton and C. Caldas, “BEX2 Is Overexpressed in a Subset of Primary Breast Cancers and Mediates Nerve Growth Factor/Nuclear Factor-KappaB Inhibition of Apoptosis in Breast Cancer Cell Lines,” Cancer Research, Vol. 67, No. 14, 2007, pp. 6725-6736.
doi:10.1158/0008-5472.CAN-06-4394
|
[16]
|
N. H. Molloy, D. E. Read and A. M. Gorman, “Nerve Growth Factor in Cancer Cell Death and Survival,” Cancers, Vol. 3, 2011, pp. 510-530.
doi:10.3390/cancers3010510
|
[17]
|
X. Tong, D. Xie, W. Roth, J. Reed, H. P. Koeffler, “NADE (p75NTR-Associated Cell Death Executor) Suppress Cellular Growth in Vivo,” International Journal of Oncology, Vol. 22, 2003, pp. 1357-1362.
|
[18]
|
T. L. Romanuik, T. Ueda, N. Le, S. Haile, T. M. Yong, T. Thomson, R. L. Vessella and M. D. Sadar, “NGFRAP1 Novel Biomarkers for Prostate Cancer Including Noncoding Transcripts,” American Journal of Pathology, Vol. 175, No. 6, 2006, pp. 2264-2276.
doi:10.2353/ajpath.2009.080868
|
[19]
|
Y. P. Ching, A. S. Pang, W. H. Lam, R. Z. Qi and J. H. Wang, “Identification of a Neuronal Cdk5 Activator- Binding Protein as Cdk5 Inhibitor,” Journal of Biological Chemistry, Vol. 277, No. 18, 2002, pp. 15237-15240.
doi:10.1074/jbc.C200032200
|
[20]
|
K. Kok, J. Osinga, D. C. Schotanus, H. H. Berendsen, L. F. de Leij and C. H. Buys, “Amplification and Expression of Different Myc-Family Genes in a Tumor Specimen and 3 Cell Lines Derived from One Small-Cell Lung Cancer Patient during Longitudinal Follow-Up,” International Journal of Cancer, Vol. 44, No. 1, 1989, pp. 75-78.
doi:10.1002/ijc.2910440114
|
[21]
|
I. I. Wistuba, A. F. Gazdar and J. D. Minna, “Molecular Genetics of Small Cell Lung Carcinoma,” Seminars in Oncology, Vol. 28, No. 2-4, 2001, pp. 3-13.
|
[22]
|
Z. Zhao, Q. Cheng, X. Li, X.Wang and K. Liu, “c-fos Antisense Oligodeoxynucleotide Reduces VIP-Induced Upregulation of VEGF Expression in Small Cell Lung Cancer Cells,” Chinese Journal of Lung Cancer, Vol. 9, No. 4, 2006, pp. 312-315.
|
[23]
|
C. A. Gilbert and A. H. Ross, “Cancer Stem Cells: Cell Culture, Markers and Targets for New Therapies,” Journal of Cellular Biochemistry, Vol. 108, No. 5, 2009, pp. 1031-1038. doi:10.1002/jcb.22350
|
[24]
|
T. W. Moody, D. Chan, J. Fahrenkrug and R. T. Jensen, “Neuropeptides as Autocrine Growth Factors in Cancer Cells,” Current Pharmaceutical Design, Vol. 9, No. 6, 2003, pp. 495-509. doi:10.2174/1381612033391621
|
[25]
|
U. Olszewski and G. Hamilton, “Neurotensin Signaling Induces Intracellular Alkalinization and Interleukin-8 Expression in Human Pancreatic Cancer Cells,” Molecular Oncology, Vol. 3, 2009, pp. 204-213.
doi:10.1016/j.molonc.2009.01.006
|
[26]
|
H. Yao, E. Ashihara and T. Maekawa, “Targeting the Wnt/β-Catenin Signaling Pathway in Human Cancers,” Expert Opinion on Therapeutic Targets, Vol. 15, No. 7, 2011, pp. 873-887.
doi:10.1517/14728222.2011.577418
|
[27]
|
B. Purow, “Notch Inhibition as a Promising New Approach to Cancer Therapy,” Advances in Experimental Medicine and Biology, Vol. 727, 2012, pp. 305-319.
doi:10.1007/978-1-4614-0899-4_23
|
[28]
|
A. C. Chang, Y. Fu, V. C. Garside, K. Niessen, L. Chang, M. Fuller, A. Setiadi, J. Smrz, A. Kyle, A. Minchinton, M. Marra, P. A. Hoodless and A. Karsan, “Notch Initiates the Endothelial-to-Mesenchymal Transition in the Atrioventricular Canal through Autocrine Activation of Soluble Guanylyl Cyclase,” Developmental Cell, Vol. 21, No. 2, 2011, pp. 288-300. doi:10.1016/j.devcel.2011.06.022
|
[29]
|
J. Wang, B. A. Sullenger and J. N. Rich, “Notch Signaling in Cancer Stem Cells,” Advances in Experimental Medicine and Biology, Vol. 727, 2012, pp. 174-185.
doi:10.1007/978-1-4614-0899-4_13
|
[30]
|
J. Lesley, R. Hyman and P. W. Kincade, “CD44 and Its Interaction with Extracellular Matrix,” Advances in Immunology, Vol. 54, 1993, pp. 271-335.
doi:10.1016/S0065-2776(08)60537-4
|
[31]
|
M. Zoller, “CD44: Can a Cancer-Initiating Cell Profit from an Abundantly Expressed Molecule?” Nature Reviews Cancer, Vol. 11, No. 4, 2011, pp. 254-267.
doi:10.1038/nrc3023
|
[32]
|
J. Huang, M. I. Che, Y. T. Huang, M. K. Shyu, Y. M. Huang, Y. M. Wu, W. C. Lin, P. H. Huang, J. T. Liang, P. H. Lee and M. C. Huang, “Overexpression of MUC15 Activates Extracellular Signal-Regulated Kinase 1/2 and Promotes the Oncogenic Potential of Human Colon Cancer Cells,” Carcinogenesis, Vol. 30, No. 8, 2009, pp. 1452-1458. doi:10.1093/carcin/bgp137
|
[33]
|
F. Siddiq, F. H. Sarkar, A. Wali, H. I. Pass and F. Lonardo, “Increased Osteonectin Expression Is Associated with Malignant Transformation and Tumor Associated Fibrosis in the Lung,” Lung Cancer, Vol. 45, No. 2, 2004, pp. 197-205.doi:10.1016/j.lungcan.2004.01.020
|
[34]
|
M. Fu, E. L. Maresh, R. A. Soslow, M. Alavi, V. Mah, Q. Zhou, A. Iasonos, L. Goodglick, L. K. Gordon, J. Braun and M. Wadehra, “Epithelial Membrane Protein-2 Is a Novel Therapeutic Target in Ovarian Cancer,” Clinical Cancer Research, Vol. 16, No. 15, 2010, pp. 3954-3963.
doi:10.1158/1078-0432.CCR-10-0368
|
[35]
|
R. O. Hynes, “The Extracellular Matrix: Not Just Pretty Fibrils,” Science, Vol. 326, No. 5957, 2009, pp. 1216-1219. doi:10.1126/science.1176009
|
[36]
|
M. Jensen and F. Berthold, “Targeting the Neural Cell Adhesion Molecule in Cancer,” Cancer Letters, Vol. 258, 2007, pp. 9-21. doi:10.1016/j.canlet.2007.09.004
|
[37]
|
S. Takahashi, K. Kato, K. Nakamura, R. Nakano, K. Kubota and H. Hamada, “Neural Cell Adhesion Molecule 2 as a Target Molecule for Prostate and Breast Cancer Gene Therapy,” Cancer Science, Vol. 102, No. 4, 2011, pp. 808-814. doi:10.1111/j.1349-7006.2011.01855.x
|
[38]
|
M. Namdarghanbari, W. Wobig, S. Krezoski, N. M. Tabatabai and D. H. Petering, “Mammalian Metallothionein in Toxicology, Cancer, and Cancer Chemotherapy,” Journal of Biologic Inorganic Chemistry, Vol. 16, No. 7, 2011, pp. 1087-1101.
|
[39]
|
J. S. Moreb, “Aldehyde Dehydrogenase as a Marker for Stem Cells,” Current Stem Cell Research and Therapy, Vol. 3, No. 4, 2008, pp. 237-246.
doi:10.2174/157488808786734006
|
[40]
|
J. Hilton, “Role of Aldehyde Dehydrogenase in Cyclophosphamide-Resistant L1210 Leukemia,” Cancer Research, Vol. 44, No. 11, 1984, pp. 5156-5160.
|
[41]
|
X. Li, L. Wan, J. Geng, C. L. W and X. Bai, “Aldehyde Dehydrogenase 1A1 Possesses Stem-Like Properties and Predicts Lung Cancer Patient Outcome,” Journal of Thoracic Oncology, 2012, in Press.
doi:10.1097/JTO.0b013e318257cc6d
|
[42]
|
D. C. Seo, J. M. Sung, H. J. Cho, H. Yi, K. H. Seo, I. S. Choi, D. K. Kim, J. S. Kim, A. El-Aty and H. C. Shin, “Gene Expression Profiling of Cancer Stem Cell in Human Lung Adenocarcinoma A549 Cells,” Molecular Cancer, Vol. 6, No. 75, 2007.
doi:10.1186/1476-4598-6-75
|
[43]
|
G. G. Wang, M. P. Pasillas and M. P. Kamps, “Meis1 Programs Transcription of FLT3 and Cancer Stem Cell Character, Using a Mechanism That Requires Interaction with Pbx and a Novel Function of the Meis1 C-Terminus,” Blood, Vol. 106, No. 1, 2005, pp. 254-264.
doi:10.1182/blood-2004-12-4664
|
[44]
|
N. Pedersen, S. Mortensen, S. B. Sorensen, M. W. Pedersen, K. Rieneck, L. F. Bovin and H. S. Poulsen, “Transcriptional Gene Expression Profiling of Small Cell Lung Cancer Cells,” Cancer Research, Vol. 63, No. 8, 2003, pp. 1943-1953.
|
[45]
|
Koomagi, G. Stammler, C. Manegold, J. Mattern and M. Volm, “Expression of Resistance-Related Proteins in Tumoral and Peritumoral Tissues of Patients with Lung Cancer,” Cancer Letters, Vol. 110, No. 1-2, 1996, pp. 129-136. doi:10.1016/S0304-3835(96)04471-0
|
[46]
|
X. Q. Liang, E. H. Cao, Y. Zhang and J. F. Qin, “A P53 Target Gene, PIG11, Contributes to Chemosensitivity of Cells to Arsenic Trioxide,” FEBS Letters, Vol. 569, No. 1-3, 2004, pp. 94-98. doi:10.1016/j.febslet.2004.05.057
|
[47]
|
A. Cormier, M. Knossow, C. Wang and B. Gigant, “The Binding of Vinca Domain Agents to Tubulin: Structural and Biochemical Studies,” Methods in Cell Biology, Vol. 95, 2010, pp. 373-390.
doi:10.1016/S0091-679X(10)95020-6
|
[48]
|
B. Ogretmen, “Sphingolipids in Cancer: Regulation of Pathogenesis and Therapy,” FEBS Letters, Vol. 580, No. 23, 2006, pp. 5467-5476.
doi:10.1016/j.febslet.2006.08.052
|
[49]
|
G. A. Patwardhan and Y. Y. Liu, “Sphingolipids and Expression Regulation of Genes in Cancer,” Progess in Lipid Research, Vol. 50, No. 1, 2011, pp. 104-114.
doi:10.1016/j.plipres.2010.10.003
|
[50]
|
M. Kohno, M. L. Momoi, J. H. Oo, Y. M. Paik, K. Lee, Venkataraman, et al., “Intracellular Role for Sphingosine Kinase 1 in Intestinal Adenoma Cell Proliferation,” Molecular Cell Biology, Vol. 26, 2006, pp. 7211-7223.
doi:10.1128/MCB.02341-05
|
[51]
|
B. Malik and D. Nie, “Cancer Stem Cells and Resistance to Chemo and Radio Therapy,” Frontiers of Bioscience, Vol. 4, 2012, pp. 2142-2149. doi:10.2741/E531
|
[52]
|
M. R. García Campelo, G. A. Curbera, G. Aparicio Gallego, E. G. Pulido and L. M. A. Aparicio, “Stem Cell and Lung Cancer Development: Blaming the Wnt, Hh and Notch Signalling Pathway,” Clinical and Translational Oncology, Vol. 13, No. 2, 2011, pp. 77-83.
doi:10.1007/s12094-011-0622-0
|
[53]
|
C. D. Salcido, A. Larochelle, B. J. Taylor, C. E. Dunbar and L. Varticovski, “Molecular Characterisation of Side Population Cells with Cancer Stem Cell-Like Characteristics in Small-Cell Lung Cancer,” British Journal of Cancer, Vol. 102, No. 11, 2010, pp. 1636-1644.
doi:10.1038/sj.bjc.6605668
|
[54]
|
R. E. Durand and P. L. Olive, “Resistance of Tumor Cells to Chemo- and Radiotherapy Modulated by the Three-Dimensional Architecture of Solid Tumors and Spheroids,” Methods in Cell Biology, Vol. 64, 2001, pp. 211-233. doi:10.1016/S0091-679X(01)64015-9
|